3 completed, 2 recruiting, 1 terminated. 5 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Sumithira Vasu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus | Early Phase 1 | Recruiting | Sumithira Vasu | 20 | 2020-11-07 | 2026-09-24 |
| Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells - Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Completed | Sumithira Vasu | 19 | 2020-06-11 | 2026-01-09 |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis - Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Terminated | Sumithira Vasu | 4 | 2020-01-10 | 2025-05-21 |
| Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies radiation therapy, cyclophosphamide, anti-thymocyte globulin - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 1 | Completed | Sumithira Vasu | 33 | 2015-07-27 | 2023-09-21 |
| Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, natural killer cell therapy, aldesleukin - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Sumithira Vasu | 8 | 2015-04-21 | 2020-03-09 |
Leukemia, Myeloid, Acute (4) · Congenital Abnormalities (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Adenoviridae Infections (1) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1)
Cyclophosphamide (2) · Antilymphocyte Serum (1) · Biopsy (1) · Blood Component Removal (1) · Cytarabine (1) · Decitabine (1) · Interleukin-2 (1) · Leukapheresis (1) · Methotrexate (1) · Peripheral Blood Stem Cell Transplantation (1) · Radiation (1) · Radiotherapy (1) · Specimen Handling (1) · Tacrolimus (1) · Transplantation (1)
United States (6)
R01CA276374 (1)